Oxford BioDynamics PLC OBD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 7.88
- Day Range
- GBX 7.50–8.00
- 52-Week Range
- GBX 7.50–52.00
- Bid/Ask
- GBX 7.80 / GBX 8.00
- Market Cap
- GBX 2.44 Bil
- Volume/Avg
- 46,147 / 586,346
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 22.79
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Oxford BioDynamics PLC is a biotechnology company. The company focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. It provides a technology platform Episwitch which aims to accelerate the drug discovery and development process and improve the success rate of therapeutic product development. Geographically, the majority of revenue is from The United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 45
Valuation
|
Metric
|
OBD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.86 |
Price/Sales | 22.79 |
Price/Cash Flow | — |
Price/Earnings
OBD
Financial Strength
|
Metric
|
OBD
|
|---|---|
Quick Ratio | 1.72 |
Current Ratio | 1.79 |
Interest Coverage | −52.91 |
Quick Ratio
OBD
Profitability
|
Metric
|
OBD
|
|---|---|
Return on Assets (Normalized) | −60.11% |
Return on Equity (Normalized) | −381.02% |
Return on Invested Capital (Normalized) | −73.32% |
Return on Assets
OBD
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pbxnjqjs | Fsb | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lppnchx | Jbbflzb | $109.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kcqlsqgh | Tntpcpf | $105.3 Bil | |
MRNA
| Moderna Inc | Bcbrrtyz | Yscq | $47.0 Bil | |
ARGX
| argenx SE ADR | Rfmfmtsv | Vvwb | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Mygkwcdf | Lxmy | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nlrffwb | Nqvvkp | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nxytvtkbs | Nxyxp | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Myzlvxgzxh | Cxwdd | $12.7 Bil | |
INCY
| Incyte Corp | Nwypdwmk | Hhmqk | $12.0 Bil |